RAXAR
LOE ApproachingNDAORALTABLET
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAXAR is an oral tablet small-molecule NDA approved by Otsuka in 1997. The mechanism of action and pharmacologic class are not publicly detailed in available data. Specific indications and patient population cannot be confirmed from current information.
LOE Approaching
Product is approaching loss of exclusivity; commercial teams are likely in transition or optimization mode with reduced headcount expectations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal current hiring for RAXAR. This is a mature product in decline, offering limited career growth or advancement potential. Roles on this team are primarily defensive, focused on maximizing remaining patent life and preparing for generic competition.
Brand ManagerField Sales Representative
Worked on RAXAR at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.